Breaking Bcr-Abl Resistance

Breaking Bcr-Abl Resistance - Giulio Superti-Furga discovers a new vulnerability of drug-resistant Bcr-Abl mutants—blocking their SH2 domain interface enhances the effectiveness of tyrosine kinase inhibitors.